MX2020008468A - Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas. - Google Patents

Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.

Info

Publication number
MX2020008468A
MX2020008468A MX2020008468A MX2020008468A MX2020008468A MX 2020008468 A MX2020008468 A MX 2020008468A MX 2020008468 A MX2020008468 A MX 2020008468A MX 2020008468 A MX2020008468 A MX 2020008468A MX 2020008468 A MX2020008468 A MX 2020008468A
Authority
MX
Mexico
Prior art keywords
urolithin
precursors
autophagy
longevity
urolitins
Prior art date
Application number
MX2020008468A
Other languages
English (en)
Other versions
MX393128B (es
Inventor
William Blanco-Bose
Bernard Schneider
Laurent Mouchiroud
Dongryeol Ryu
Penelope Andreux
Johan Auwerx
Christopher L Rinsch
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020008468(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2020008468A publication Critical patent/MX2020008468A/es
Publication of MX393128B publication Critical patent/MX393128B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)

Abstract

La presente invención se refiere a métodos, compuestos, y composiciones útiles para incrementar la autofagia y promover la longevidad. Los métodos, compuestos, y composiciones se refieren a urolitinas y precursores de urolitinas y uso de las mismas. Ciertas urolitinas son representadas por la Fórmula I, mientras ciertos receptores de urolitina están representados por la Fórmula IV. La urolitina puede ser urolitina A, urolitina B, urolitina C, o urolitina D. El precursor de urolitina puede ser ácido elágico o una elagitanina. Los métodos incluyen usos in vivo, ex vivo, e in vitro de los compuestos y composiciones.
MX2020008468A 2012-06-27 2013-06-27 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas MX393128B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US201361791137P 2013-03-15 2013-03-15
PCT/US2013/048310 WO2014004902A2 (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Publications (2)

Publication Number Publication Date
MX2020008468A true MX2020008468A (es) 2022-06-14
MX393128B MX393128B (es) 2025-03-24

Family

ID=48782652

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020008468A MX393128B (es) 2012-06-27 2013-06-27 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas
MX2014016044A MX378354B (es) 2012-06-27 2013-06-27 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
MX2022007264A MX2022007264A (es) 2012-06-27 2014-12-19 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014016044A MX378354B (es) 2012-06-27 2013-06-27 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
MX2022007264A MX2022007264A (es) 2012-06-27 2014-12-19 Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.

Country Status (16)

Country Link
US (10) US11020373B2 (es)
EP (3) EP4566677A3 (es)
JP (5) JP6422163B2 (es)
KR (4) KR20210128511A (es)
CN (2) CN105142632B (es)
AR (1) AR091604A1 (es)
AU (6) AU2013284419A1 (es)
BR (1) BR112014032809A8 (es)
CA (3) CA3127211C (es)
DK (1) DK4233858T3 (es)
ES (2) ES3032009T3 (es)
MX (3) MX393128B (es)
PL (1) PL4233858T3 (es)
PT (2) PT4233858T (es)
SG (3) SG10202106329TA (es)
WO (1) WO2014004902A2 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
WO2014111580A1 (en) * 2013-01-18 2014-07-24 Procell Sprl Urolithin b for muscle growth
AU2014317857B2 (en) * 2013-09-09 2020-01-02 Natreon, Inc. Regulation of body weight gain by using dibenzo-alpha-pyrones
EP2862568A1 (en) * 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
EP3663287B1 (en) 2013-12-23 2023-09-20 Amazentis SA Process scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) * 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
WO2016099947A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
WO2016167225A1 (ja) * 2015-04-13 2016-10-20 住友精化株式会社 ２－ハロゲン化安息香酸類の製造方法
JP6740548B2 (ja) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する５αレダクターゼ活性阻害剤
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
AU2016375177B2 (en) * 2015-12-24 2022-09-01 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin
JP2017210444A (ja) * 2016-05-26 2017-11-30 株式会社ダイセル ウロリチン類を含有するリパーゼ阻害剤
JP6791478B2 (ja) * 2016-05-26 2020-11-25 株式会社ダイセル ウロリチン類を含有するアンジオテンシン変換酵素阻害剤
ES2985944T3 (es) * 2016-06-29 2024-11-07 Halo Life Science Llc Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor
WO2018013568A1 (en) * 2016-07-11 2018-01-18 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
US11634686B2 (en) 2016-11-01 2023-04-25 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
JP7761372B2 (ja) * 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20180256471A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
JP2019097566A (ja) * 2017-12-07 2019-06-24 大正製薬株式会社 体内時計調整用組成物
EP3727419A1 (en) * 2017-12-20 2020-10-28 Société des Produits Nestlé S.A. Compositions and methods using a combination of autophagy inducer and high protein for induction of autophagy
WO2019121855A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
AU2018408840A1 (en) * 2018-02-19 2020-09-10 Natreon, Inc. Synergistic combinations of Urolithins A and B for improving cognitive capacity or cognitive function
WO2019163437A1 (ja) 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
AU2019227733B2 (en) * 2018-02-27 2024-08-01 Amazentis Sa Process-scale synthesis of urolithin A
JP7217542B2 (ja) * 2018-03-29 2023-02-03 国立大学法人 琉球大学 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
CA3100335A1 (en) 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
JP2021527048A (ja) * 2018-06-05 2021-10-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 癌治療のためのアシル化カテキンポリフェノールおよびその使用方法
AU2019282691A1 (en) 2018-06-05 2020-12-24 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN108676013B (zh) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN109316478A (zh) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
PL245399B1 (pl) 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
CN110066284B (zh) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 一种一锅法合成鞣花酸的方法
CN110229167B (zh) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 一种利用五倍子制备鞣花酸的方法、制得的鞣花酸及其应用
CN111995610A (zh) * 2019-05-27 2020-11-27 首都医科大学 一种尿石素类化合物用于治疗胶质母细胞瘤药物的应用
WO2020257283A1 (en) * 2019-06-18 2020-12-24 Mitopower Llc Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) * 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
EP4065102A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
JP2023503276A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用
CN113018305A (zh) * 2019-12-24 2021-06-25 兰州大学 一种化合物在制备治疗阿尔兹海默症药物中的应用
WO2021163802A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
WO2022016138A2 (en) * 2020-07-17 2022-01-20 The Trustees Of Columbia University In The City Of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (zh) * 2020-07-30 2023-06-23 云南中医药大学 中药抗非酒精性脂肪肝活性物质的筛选方法
US20220071952A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
KR102690860B1 (ko) * 2021-10-13 2024-08-05 한국해양과학기술원 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
AU2022378931A1 (en) * 2021-10-28 2024-02-22 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CA3258478A1 (en) * 2022-06-06 2023-12-14 Amazentis Sa Urolithines to improve heart function and health
US20240139149A1 (en) * 2022-07-27 2024-05-02 Vandria Sa Therapeutic uses of urolithin derivatives
CN115433151A (zh) * 2022-09-02 2022-12-06 苏州大学 一种6，7，8-三羟基香豆素的制备方法
CN115581689B (zh) * 2022-10-17 2024-05-14 常州大学 尿石素b酰胺类衍生物的应用
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN116966188B (zh) * 2023-07-14 2026-04-03 天津医科大学总医院 丁香素在制备治疗和/或预防炎症性肠病药物中的应用
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
WO2025076497A1 (en) * 2023-10-06 2025-04-10 Northeast Ohio Medical University Combination treatment of tau pathology
WO2025078645A1 (en) * 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
FR3153998A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
FR3153997A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
FR3153996A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
CN117771237B (zh) * 2024-02-27 2024-05-03 南昌医学院 一种松香烷型二萜化合物的用途和制备方法
WO2025194036A1 (en) * 2024-03-14 2025-09-18 Washington University Autophagy enhancers
WO2025224366A1 (en) 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
US20250381110A1 (en) * 2024-06-17 2025-12-18 The Procter & Gamble Company Skin care composition and method of using the same
GB202411739D0 (en) 2024-08-08 2024-09-25 Amazentis Sa Compositions
CN119792272B (zh) * 2025-02-07 2025-10-03 陕西中鸿科瑞再生医学研究院有限公司 一种改善睡眠的组合物及其制备方法与制剂

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
US6066312A (en) 1996-07-16 2000-05-23 Lion Corporation Topical composition for application to the skin containing an ellagic acid-based compound or salt thereof
ES2235499T3 (es) 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US7727563B2 (en) 1999-04-19 2010-06-01 Pom Wonderful, Llc Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans
US7611738B2 (en) 2005-05-24 2009-11-03 Pom Wonderful, Llc Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20080039179A1 (en) 2001-06-27 2008-02-14 Seelig Jerald C Gaming display with moveable indicator and methods of use
US6953241B2 (en) 2001-11-30 2005-10-11 Brother Kogyo Kabushiki Kaisha Ink-jet head having passage unit and actuator units attached to the passage unit, and ink-jet printer having the ink-jet head
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
ES2543981T3 (es) 2004-03-24 2015-08-26 The Regents Of The University Of California Purificaciones de elagitaninos
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
BRPI0708318A2 (pt) 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
WO2007127263A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8367072B2 (en) 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2008139123A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
EP2155186A2 (fr) * 2007-05-11 2010-02-24 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
US20090105196A1 (en) * 2007-06-22 2009-04-23 Belinda Tsao Nivaggioli Use of creatine compounds to treat dermatitis
EP2033526A1 (en) 2007-09-07 2009-03-11 Probelte Pharma, S.A. Nutritional products comprising pomegranate extracts containing ellagitannins and their use
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110021618A1 (en) 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US7927633B2 (en) 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea
WO2009153652A2 (en) 2008-06-19 2009-12-23 Avesthagen Limited An extract and a process thereof (pomplex)
US20100004334A1 (en) 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
CN101301319A (zh) 2008-07-09 2008-11-12 中国科学院新疆理化技术研究所 石榴花多酚的制备方法及其应用
US20100055247A1 (en) 2008-08-29 2010-03-04 Tirrito Salvatore J Nutritional Compositions for Athletes
AU2010233073B2 (en) * 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
MX353338B (es) 2010-12-08 2018-01-09 Georgia Pacific Nonwovens Llc Material de limpieza no tejido dispersable.
JP6054301B2 (ja) * 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
US8772252B2 (en) 2011-01-27 2014-07-08 New York University Coumarin compounds as melanogenesis modifiers and uses thereof
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2012113835A1 (en) 2011-02-22 2012-08-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
EP3663287B1 (en) 2013-12-23 2023-09-20 Amazentis SA Process scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
CA2963277A1 (en) 2014-10-02 2016-04-07 Natreon, Inc. Promoting muscle building and repair and treating disorders related to collagen and pertinent proteins by using shilajit
US10111842B2 (en) 2014-12-31 2018-10-30 University Of Oslo Eutectic solvents and uses thereof
JP2016216378A (ja) 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017007951A (ja) 2015-06-17 2017-01-12 公立大学法人岡山県立大学 ウロリチンを含有する光老化抑制剤
JP2017014154A (ja) 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
JP2017031108A (ja) 2015-08-04 2017-02-09 公立大学法人岡山県立大学 ウロリチン類を含有する、抗しわ剤、コラーゲン産生促進剤、ｍｍｐ−１産生抑制剤、及びエラスターゼ活性阻害剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
KR102546379B1 (ko) 2015-10-22 2023-06-21 에이지씨 가부시키가이샤 배선 기판의 제조 방법
AU2016375177B2 (en) 2015-12-24 2022-09-01 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin
WO2017135286A1 (ja) 2016-02-02 2017-08-10 株式会社ダイセル ウロリチン類含有水溶液、その乾燥固形組成物、および、それらの製造方法、ならびにウロリチン類の安定化方法
DE202016102778U1 (de) 2016-05-25 2017-08-28 Bobst Bielefeld Gmbh Klapplager
US20180256538A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
US20180256471A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
JP7761372B2 (ja) 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20180296464A1 (en) 2017-04-17 2018-10-18 W Skincare, LLC Autophagy activation nutrient complex, compositions and methods
US10485363B2 (en) 2017-05-21 2019-11-26 Go Smart, Inc. Inflatable pillow with adjustable height
DE102017131226A1 (de) 2017-12-22 2019-06-27 Dewertokin Gmbh Elektromotorischer Möbelantrieb, Möbel und Verfahren zum Erfassen einer Position eines elektromotorischen Möbelantriebs
AU2019227733B2 (en) 2018-02-27 2024-08-01 Amazentis Sa Process-scale synthesis of urolithin A
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
WO2019228971A1 (en) 2018-05-28 2019-12-05 Lm Wind Power International Technology Ii Aps Connecting element for a lightning protection system of a wind turbine blade
US12288430B2 (en) 2018-07-09 2025-04-29 Shimano Inc. Information processing device
US20200085895A1 (en) 2018-09-13 2020-03-19 Verdure Sciences Punicalagin compositions and methods for the treatment of disorders arising from methylglyoxal-induced dna damage
CN109316478A (zh) 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
JP7446318B2 (ja) 2019-01-28 2024-03-08 キョーセラ・エイブイエックス・コンポーネンツ・コーポレーション 超広帯域性能を有する積層セラミックコンデンサ
CN110244079B (zh) 2019-07-18 2019-12-20 西南石油大学 一种控缝高上浮剂上浮速率的测试方法
GB201910450D0 (en) 2019-07-22 2019-09-04 Iiaa Ltd Cosmetic compositions
US11016804B2 (en) 2019-08-02 2021-05-25 Argo AI, LLC Ahead of time scheduling process for autonomous vehicles
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
CN110368476A (zh) 2019-08-29 2019-10-25 中南大学湘雅医院 一种治疗骨肉瘤的手术辅助药物
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
DE102020200633A1 (de) 2020-01-21 2021-07-22 Jungheinrich Aktiengesellschaft Doppelpedalsystem für ein Flurförderzeug
US11205053B2 (en) 2020-03-26 2021-12-21 International Business Machines Corporation Semantic evaluation of tentative triggers based on contextual triggers
WO2021237214A1 (en) 2020-05-22 2021-11-25 Ilera Derm LLC Compositions for treating acne and dermatological conditions
EP4153306A4 (en) 2020-05-22 2024-06-26 Ilera Derm LLC Compositions for treating acne and dermatological conditions
WO2022158533A1 (en) 2021-01-20 2022-07-28 Ajinomoto Co., Inc. Cosmetic composition
CN112843049A (zh) 2021-02-02 2021-05-28 邯郸制药股份有限公司 一种组合物用于制备基于调控CDKs和SMAD6基因抑制胃癌细胞增殖药物的用途
CN113171319B (zh) 2021-05-07 2022-03-08 宝萃生物科技有限公司 一种即时、长效抗衰除皱的复合植物提取物及其制备方法和应用
CN113476362B (zh) 2021-06-23 2022-09-13 植物医生(广东)生物科技有限公司 一种面部皮肤角质更新促进剂及其应用
WO2023031673A1 (en) 2021-08-30 2023-03-09 Amazentis Sa Treating long covid-19 with urolithins
CN113855758A (zh) 2021-11-02 2021-12-31 顾佳圻 一种益寿补钙丸及其制备方法
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CN114794490B (zh) 2022-05-25 2023-07-25 江南大学 一种具有抗皮肤光老化及辅助减脂功能的组合物
CA3258478A1 (en) 2022-06-06 2023-12-14 Amazentis Sa Urolithines to improve heart function and health
WO2024246601A1 (en) 2023-05-26 2024-12-05 Amazentis Sa Compositions comprising trigonelline and urolithin
AU2024279527A1 (en) 2023-05-26 2026-01-15 Amazentis Sa Urolithin for improving performance in elite and sub-elite athletes
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
CN116889583B (zh) 2023-08-26 2024-07-23 琛蓝(美国)营养制品股份有限公司 一种富含稀有人参皂苷的人参提取物的制备方法及其应用
WO2025078645A1 (en) 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
FR3153998A1 (fr) 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Also Published As

Publication number Publication date
AU2013284419A1 (en) 2015-02-12
ES3032009T3 (en) 2025-07-14
US20140018415A1 (en) 2014-01-16
US9962366B2 (en) 2018-05-08
US20200397748A1 (en) 2020-12-24
AU2018202407A1 (en) 2018-04-26
WO2014004902A3 (en) 2014-03-06
US20210353591A1 (en) 2021-11-18
PL4233858T3 (pl) 2025-06-09
US20160000753A1 (en) 2016-01-07
JP7339296B2 (ja) 2023-09-05
BR112014032809A2 (pt) 2017-06-27
JP6879980B2 (ja) 2021-06-02
MX393128B (es) 2025-03-24
MX378354B (es) 2025-03-10
US11020373B2 (en) 2021-06-01
AU2024259763A1 (en) 2024-11-21
JP2023107934A (ja) 2023-08-03
AU2022200876A1 (en) 2022-03-03
EP2866804A2 (en) 2015-05-06
US11931336B2 (en) 2024-03-19
CA3127211C (en) 2026-04-07
AU2020200420B2 (en) 2021-11-11
MX2014016044A (es) 2015-05-12
ES2968368T3 (es) 2024-05-09
US11931335B2 (en) 2024-03-19
JP6422163B2 (ja) 2018-11-14
CA3291904A1 (en) 2026-03-02
PT4233858T (pt) 2025-05-15
AU2022200876B2 (en) 2024-08-15
KR102317160B1 (ko) 2021-10-25
EP4566677A3 (en) 2025-09-03
US12544358B2 (en) 2026-02-10
AU2018202407B2 (en) 2019-11-21
CA3127211A1 (en) 2014-01-03
CA2877718C (en) 2021-10-12
JP2025161884A (ja) 2025-10-24
AR091604A1 (es) 2015-02-18
US20230233523A1 (en) 2023-07-27
AU2018200791B2 (en) 2019-10-31
US20180015069A1 (en) 2018-01-18
KR20230116091A (ko) 2023-08-03
CN105142632B (zh) 2020-01-07
EP4566677A2 (en) 2025-06-11
BR112014032809A8 (pt) 2021-06-22
US12576065B2 (en) 2026-03-17
CN110934863A (zh) 2020-03-31
JP2015523362A (ja) 2015-08-13
CN105142632A (zh) 2015-12-09
DK4233858T3 (da) 2025-05-12
US20250228817A1 (en) 2025-07-17
SG11201408539UA (en) 2015-01-29
AU2018200791A1 (en) 2018-02-22
JP2021119180A (ja) 2021-08-12
JP2018184455A (ja) 2018-11-22
CA2877718A1 (en) 2014-01-03
KR20200116176A (ko) 2020-10-08
SG10201610798QA (en) 2017-02-27
EP4233858B1 (en) 2025-02-12
US20250228816A1 (en) 2025-07-17
US20230390238A1 (en) 2023-12-07
PT2866804T (pt) 2023-12-18
KR20210128511A (ko) 2021-10-26
EP2866804B1 (en) 2023-09-13
MX2022007264A (es) 2022-07-13
KR20150036224A (ko) 2015-04-07
KR102163091B1 (ko) 2020-10-08
US20250375415A1 (en) 2025-12-11
EP4233858A1 (en) 2023-08-30
AU2020200420A1 (en) 2020-03-05
WO2014004902A2 (en) 2014-01-03
SG10202106329TA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CY1116439T1 (el) Τριαζολοπυριδινες
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
UY35155A (es) Derivados cíclicos de nucleósidos y usos de los mismos
ECSP14013215A (es) Compuestos novedosos
DOP2015000076A (es) Benzamidas
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
UY32404A (es) 4-aril-butan-1,3-diamidas
UY32748A (es) 2-carboxamida-cicloamino-ureas
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
MX2013007504A (es) Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina.
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas